Abstract: The present disclosure provides binding proteins, such as antibodies and binding fragments thereof, that bind beta klotho, including human beta klotho, and methods of their use, including in the treatment of nonalcoholic steatohepatitis. The present disclosure also provides exemplary specific sequences of complementarity determining regions, variable regions, heavy chains, and light chains of the antibodies and/or binding fragments thereof.

Abstract: Described herein are compositions and methods for making and using recombinant bacteria that are capable of regulated attenuation and/or regulated expression of one or more antigens from Clostridium Perfringens as vaccines to prevent necrotic enteritis (NE).

Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.

Abstract: The present disclosure relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present disclosure provides a composition comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleic acid molecule encoding a HCV antigen, an HCV antigen, an adjuvant, or a combination thereof.

Abstract: A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections.

Abstract: The present invention relates to the field of (vector) vaccines, and especially to the novel EHV insertion site UL43. The present invention further concerns related expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

Abstract: A method of reducing a latent HIV-specific memory-CD4+ T cell pool in a subject includes administering to the subject at least one HIV-1 protein and a pharmaceutically acceptable carrier, wherein the at least one HIV-1 protein is derived from an allogenic infecting HIV-1 virus, and wherein the HIV-1 protein stimulates latent HIV-specific memory CD4+ T cells to induce latent HIV-1 replication resulting in HIV-specific memory-CD4+ T cell death in the subject.

Abstract: Engineered Influenza polynucleotides, viruses, vaccines, and methods of making and using the same are provided. More specifically, the present inventors have developed replication competent engineered influenza viruses having, for example, a modified segment 4 and/or segment 6 that include at least one additional polynucleotide encoding a heterologous polypeptide.

Abstract: The present disclosure provides a method of dispersing agglomerated material in a preparation comprising influenza proteins. The method comprises subjecting the preparation to sonication.

Abstract: Compositions are provided comprising messenger RNA constructs having at least one open reading frame (ORF), wherein the ORF is operatively linked to at least one untranslated region (UTR), wherein the UTR comprises at least one organ protection sequence (OPS), wherein the OPS sequence comprises at least a first, a second and a third micro-RNA (miRNA) target sequence, and wherein each of the at least a first, second and third the miRNA target sequences are optimised to hybridise with a corresponding miRNA sequence. The compositions and molecules provided are useful in therapies such as for the treatment of cancer, in immunotherapies, and in vaccines.

Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus protein antigens and an Infectious Bursal Disease virus protein antigen, and methods of their use in poultry vaccines.

Abstract: The invention provides methods for treating patients with anti-?4?7 antibody comprising predicting outcome of the antibody therapy. The invention relates to the identification of patients who can respond to therapy comprising an anti-?4?7 antibody.

Abstract: Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.

Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-33 (hIL-33). The formulations may contain, in addition to an anti-IL-33 antibody, a buffer, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stresses.

Abstract: This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same.

Abstract: The present application relates to conjugates of STING agonists and small molecule modulators of the PD-1/PD-L1 protein/protein interaction, as well as methods of treating cancer using the conjugates.

Abstract: Provided is an antibody-drug conjugate (ADC) using one or more cysteine or derivatives thereof as linkers to couple one or more drugs at the limited binding sites of an antibody, making it possible to produce an ADC product with high drug payload, or to choose a drug with less toxicity, thereby obtaining an ADC product with wide therapeutic window. In addition, since a plurality of drugs may be coupled to one binding site, the ADC products obtained by the method of the present disclosure have better uniformity in the case of same DAR value. Moreover, the amount of antibody required for production may be greatly reduced, thereby lowering the cost. Compared with the antibody-drug conjugates coupled only one drug, the antibody-drug conjugates produced by the method of the present disclosure have the same inhibition or killing effect on tumor cells while using fewer drugs for coupling to the same site.

Abstract: This disclosure provides reagents and methods of predicting the responsiveness of a patient to NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates).

Abstract: The present invention provides specific sites for modifying antibodies or antibody fragments by replacing at least one native amino acid in the constant region of a parental antibody or antibody fragment with cysteine, which can be used as a site of attachment for a payload or linker-payload combination.

Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Abstract: Conjugates comprising a drug, cell or biological molecule bound to a photoluminescent polymer nanoparticle, in particular a cross-linked polyfluorene nanoparticle, are described herein, as well as their methods of manufacture and their uses in biological imaging and sensing applications.

Abstract: The present invention concerns synthetic polynucleotides encoding a human fukutin-related protein (FKRP) wherein the synthetic polynucleotides contain at least a mutation avoiding supplementary transcript(s) generated from frameshift start codon(s). The synthetic polynucleotides are useful, especially for treating a pathology linked to a FKRP deficiency or induced by a defect in ?-dystroglycan (?-DG) glycosylation, such as LGMD2I.

Abstract: The present invention relates to a RNA encoding an antibody or a fragment or variant thereof and a composition, in particular a passive vaccine, comprising such an RNA. The present invention further relates to the use of such an RNA or of such a composition for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention also relates to a combination of at least two modified RNA's, in particular wherein one RNA encodes a heavy chain variable region of an antibody and another RNA encodes the corresponding light chain variable region of said antibody.

Abstract: The present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels.

Abstract: The invention relates to a disinfection process comprising the feed materials H2O2 and NO2? and a mixing step and a distribution step, wherein the mixing step and the distribution step (during which each point on the surface being disinfected is wetted with a solution of active substance) are implemented during a processing period ZA. An exposure step follows, in which the distributed solution of active substance acts upon the surface in contact with the solution of active substance during an exposure period ZE. In this process, the maximum NO2? concentration during the mixing step is of 300 mM, and the time-integrated reaction rate W is represented during the exposure period ZE by the integral formula (I), where k1 denotes the pH-value-dependent speed constant of the reaction between H2O2 and NO2? and the pH value of the solution of active substance before it contacts the surface being disinfected lies in the range of 2.1?pH?6.8.

Abstract: A container for sterilizing flexible bags can be for pharmaceutical use. The container includes an upper flat structure including at least one element supporting the flexible bags and designed to accommodate a plug port of the flexible bag. The support element includes at least one fastening element, which is suitable for retaining the flexible bags once they are inserted into the support element. The container also includes a lower receptacle designed to contain the upper flat structure and to couple to the upper flat structure in a detachable manner. The container further includes a cap for hermetically sealing the lower receptacle.

Abstract: A personal protective equipment sanitizing assembly includes a cabinet that is comprised of a translucent material to pass light therethrough. An upper door is hingedly coupled to the cabinet and a lower door is hingedly coupled to the cabinet. A cart is rollably positioned in the cabinet and the cart is rollable onto the lower door when the lower door is opened for accessing the cart. A carousel unit is rotatably coupled to the cart and the carousel unit includes a plurality of suspensions to support a respective one of a plurality of face masks or other personal protective equipment. A plurality of light emitters is each coupled to the cart to emit light onto the carousel unit. Each of the light emitters has an operational wavelength ranging between approximately 10.0 nm and 400.0 nm for sterilizing the face masks.

Abstract: The present disclosure relates to an article for detecting a disinfectant via visual feedback. The article have a first substrate with a first major surface and opposite ends. The article also comprises a process indicator disposed on at least a portion of the first major surface. The process indicator reacts with at least one liquid disinfectant selected from the group consisting of glutaraldehyde, ortho-phthalaldehyde, hydrogen peroxide, peroxyacetic acid, and combinations thereof. The process indicator can be formed from a synthetic amine-containing polymer derived from polyethylenimine (PEI). The article can have a flow channel that is formed by a portion of the process indicator and that extends between the opposite ends. The disclosure also relates to a kit containing the article as well as a method of using the article in a disinfection process. The article is used to diagnose issues in an automated endoscope reprocessors (AERs).

Abstract: The present invention relates to a kit for checking the quality of cleaning of medical devices in situ comprising a staining solution by soaking comprising a colorant in a dilution phase compatible with the requirements of the medical environment, and a developing solution by soaking comprising said dilution phase.

Abstract: An ultraviolet air sterilizer for disinfecting bacterium and virus includes a shell, a sandwich activated carbon cloth filter element, a nanometer titanium dioxide screen filter, an ultraviolet light source, a heat sinking kit, and a fan. The shell includes a shell body and a cover plate. The shell body is provided with an air inlet and an opening. The cover plate is provided with an air outlet. The sandwich activated carbon cloth filter element, the nanometer titanium dioxide screen filter, the heat sinking kit and the fan are arranged sequentially along an air path from the air inlet to the air outlet. The ultraviolet light source is configured for emitting ultraviolet light to the nanometer titanium dioxide screen filter. The air sterilizer has a compact small-sized structure and effectively removes ambient gaseous as well as particulate pollutants and kills micro-organisms harmful to health and well being.

Abstract: An ionizing device is described, comprising a tubular bulb made of electrically insulating or dielectric material extending along a longitudinal reference axis and having the two longitudinal open ends and opposite each other, a tubular cathode engaged in the bulb, a tubular anode fitted to the bulb, a pair of covers, each of which has a respective internal seat into which a respective end of the bulb is inserted so as to hermetically seal it, and a conductive electrode which extends into the bulb and is electrically connected to the cathode.

Abstract: A medical polymer device comprising a biodegradable polymer is provided, wherein the biodegradable polymer has a crystallinity of about 10% to about 80%, and preferably from about 20% to about 60%, wherein the medical polymer device comprises a small molecule organic compound which diffuses into the biodegradable polymer, the small molecule organic compound has a molecular weight of from about 100 to about 1000 Daltons, preferably from about 150 to about 500 Daltons, and more preferably from about 150 to about 250 Daltons, and the small molecule organic compound is non-evaporating or low-evaporating. The present invention also provides a method for preparing a medical polymer device according to the present invention as well as a method for modifying a medical polymer device made from a biodegradable polymer.

Abstract: Novel surgical sutures and novel medical devices made from novel semi-crystalline, glycolide-rich A-B-A triblock copolymers of glycolide and lactide, wherein said B-segment is a fully amorphous random copolymer of glycolide and lactide, for long term medical applications are disclosed. The novel polymer compositions are useful for long term absorbable surgical sutures, meshes and other medical devices, especially for patients with compromised healing. The novel sutures have improved properties and improved breaking strength retention, while still substantially absorbing within about a 120-day period post-implantation.

Abstract: Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

Abstract: The present invention relates to methods for removing antigens from tissues by sequentially destabilizing and/or depolymerizing cytoskeletal components and removing and/or reducing water-soluble antigens and lipid-soluble antigens. The invention further relates to tissue scaffolding and decellularized extracellular matrix produced by such methods.

Abstract: An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects, a method of preparation thereof, and a method of inducing or promoting bone growth by treatment of a bone with an autologous bone graft substitute composition. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof; and a compression resistant matrix selected from the group consisting of a bone autograft, bone allograft, hydroxyapatite, tri-calcium phosphate, and combinations thereof. The autologous blood forms a coagulum gel comprising a fibrin-meshwork reinforced with the compression resistant matrix and containing the osteogenic bone morphogenetic protein which is released over a sustained period.

Abstract: The present invention relates to a tissue-engineered intervertebral disc (IVD) comprising a nucleus pulposus structure comprising a first population of living cells and an annulus fibrosis structure surrounding and in contact with the nucleus pulposus structure, the annulus fibrosis structure comprising a second population of living cells and collagen.

Abstract: Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.

Abstract: This invention relates, e.g., to a Myocyte-based Flow Assist Device (MFAD) for treating a subject in need of increased flow of a biological fluid, such as venous blood or lymph, comprising a sheath which comprises rhythmically contracting myocytes.

Abstract: Compositions of small molecules, matrices, and isolated cells including methods of preparation, and methods for differentiation, trans-differentiation, and proliferation of animal cells into the osteoblast cell lineage were described. Examples of osteogenic materials that were administered to cells or co-cultured with cells are represented by compounds of Formula II, IV, and VI independently or preferably in combination with a matrix to afford bone cells. Small molecule-stimulated cells were also combined with a matrix, placed with a cellular adhesive or material carrier and implanted to a site in an animal for bone repair. Matrix pretreated with compounds of Formula II, IV, and VI were also used to cause cells to migrate to the matrix that is of use for therapeutic purposes.

Abstract: A three-dimensional electrospun biomedical patch includes a first polymeric scaffold having a first structure of deposited electrospun fibers extending in a plurality of directions in three dimensions to facilitate cellular migration for a first period of time upon application of the biomedical patch to a tissue, wherein the first period of time is less than twelve months, and a second polymeric scaffold having a second structure of deposited electrospun fibers. The second structure of deposited electrospun fibers includes the plurality of deposited electrospun fibers configured to provide structural reinforcement for a second period of time upon application of the three-dimensional electrospun biomedical patch to the tissue wherein the second period of time is less than twelve months. The three-dimensional electrospun biomedical patch is sufficiently pliable and resistant to tearing to enable movement of the three-dimensional electrospun biomedical patch with the tissue.

Abstract: The present invention relates to biomaterials coated with an active agent eluting coating, wherein implantation of the coated biomaterial results in reduced implant-related complications and/or improved integration of the biomaterial into the host tissue and further relates to kits containing the coated biomaterial. The present invention also relates to methods and kits for coating the biomaterial. It is based, at least in part, on the discovery that biomaterial coated with a cytokine eluting coating resulted in the shift of early stage macrophage polarization that were associated with positive long-term effects such as minimized capsule formation and improved tissue quality and composition as compared to uncoated biomaterials.

Abstract: This adhesion prevention film for medical devices is a single-layer or multilayer adhesion prevention film that is formed on the surface of a medical device. This adhesion prevention film for medical devices comprises an outermost layer that contains a plurality of conductive particles and a resin having a continuously usable temperature of 200° C. or higher. The surface of the outermost layer is provided with recesses and projections by having parts of the plurality of conductive particles exposed from the resin.

Abstract: A method of incorporating silver and/or copper into a biomedical implant includes: providing an implant having an outer surface; depositing silver and/or copper onto the outer surface of the implant; diffusing the silver and/or copper into a subsurface zone adjacent the outer surface; and oxidizing or anodizing the implant after the diffusion step to form an oxidized or anodized layer that contains at least some amount of elemental silver, elemental copper or silver or copper ions or compounds.

Abstract: This disclosure relates to dialysis systems and methods. In some implementations, a dialysis system includes a dialysis machine with a fluid line and a drain line, a blood line set configured to be connected to the dialysis machine, and a drain apparatus coupled to the dialysis machine. The drain apparatus includes a chamber configured to receive an end of a patient line of the blood line set, an inlet line, an outlet line, and a valve. The inlet line has a first end configured to be coupled to the chamber and a second end configured to be coupled to the fluid line of the dialysis machine. The outlet line has a first end configured to be coupled to the chamber and a second end configured to be coupled to the drain line of the dialysis machine. The valve is configured to control flow of fluid through the outlet line.

Abstract: Flow capture device and method for removing cells from blood The current invention discloses a blood treating and/or purifying device for removing circulating pathogens, preferably pathogenic cells, more preferably circulating tumor cells from the blood of a patient, a method of producing such a device and method to treat cancer and other diseases caused by virus infection, bacterial infection and parasites infection as well as autoimmune disorders. The described method is an extracorporeal medical therapy, thus can be done also in a hemodialysis system. The current invention also describes a device and an in-situ production method of preparing the device to remove CTC and other pathogens i.e. virus, bacteria or parasites from the bloodstream.

Abstract: A system for monitoring percentage change in blood volume (?BV %) during dialysis treatment includes a sensor device configured to obtain hematocrit (Hct)-related measurements based on detecting light which has passed through extracorporeal blood of a patient undergoing the dialysis treatment; one or more controllers configured to: determine Hct values based on the Hct-related measurements obtained by the sensor device; determine ?BV % values based on the determined Hct values; and generate a GUI having a ?BV % plot based on the determined ?BV % values; and a display device having a display configured to display the GUI having the ?BV % plot. Zone indicators are provided on the display to distinguish between a first zone corresponding to a first ?BV % profile, a second zone corresponding to a second ?BV % profile, and a third zone corresponding to a third ?BV % profile.

Abstract: A filter and a device including the filter may include a filter and a plurality of pores arranged two-dimensionally on the filter. The plurality of pores may include a plurality of first pores having a longer structure in a certain direction and a plurality of second pores having a longer structure in a direction different from that of the first pore. The first and second pores may have a two-dimensional arrangement in order to suppress or prevent the occurrence of cracks in the filter due to stress.

Abstract: The invention relates to a device for extracorporeal blood treatment, comprising a blood treatment unit 1 that comprises at least one compartment 4. The invention further relates to a method for determining a hemodynamic parameter during an extracorporeal blood treatment by means of an extracorporeal blood treatment device. In order to determine the hemodynamic parameter, the conveying direction of the blood pump 10 is reversed from a “normal” blood flow to a “reversed” blood flow. In practice, it has been found that reversing the conveying direction of the blood pump for a measurement for determining a hemodynamic parameter carries the risk of blood clots reaching the patient, despite the dialyser holding back blood clots. The blood treatment device comprises an input unit 23 for inputting a time interval which can be specified by the user, taking into account the patient-specific and system-specific factors.